JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 January 2008

J Clin Pathol. Published Online First: 27 April 2007. doi:10.1136/jcp.2007.048694
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jcp.2007.048694v1
61/1/64    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selvarajan, S.
Right arrow Articles by Tan, P.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selvarajan, S.
Right arrow Articles by Tan, P.-H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Breast Cancer

Histopathology

Parafibromin expression in breast cancer: a novel marker for prognostication?

Sathiyamoorthy Selvarajan 1, Lang Hiong Sii 1, Adrian Lee 1, George Yip 2, Boon Huat Bay 2, Min Han Tan 3, Bin-Tean Teh 4 and Puay-Hoon Tan 1*

1 Singapore General Hospital, Singapore
2 National University of Singapore, Singapore
3 National Cancer Centre, Singapore
4 Van Andel Research Institute, United States

* To whom correspondence should be addressed. E-mail: gpttph{at}sgh.com.sg.

Accepted 2 April 2007


*   Abstract

Objectives: Parafibromin, a novel protein product of HRPT2, is a recently identified tumor suppressor gene. Mutations of the HRPT2 gene are common in parathyroid carcinoma, and parathyroid carcinomas exhibit reduced protein expression. Parafibromin expression in breast cancer has not been previously studied. We aimed to determine the distribution of this protein in breast cancer tissues, and correlate its expression with conventional pathologic parameters.

Materials and methods: Tissue microarrays (TMAs) were constructed from archival paraffin embedded breast cancers diagnosed at the Department of Pathology, Singapore General Hospital. Sections cut from TMA blocks were subjected to immunohistochemistry. Immunopositivity for parafibromin and intensity-percentage scores were derived by blinded evaluation. Findings were correlated with clinicopathological parameters.

Results: A total of 163 breast cancers was assessed. Larger tumors were less likely to express parafibromin than smaller ones, with the association approaching statistical significance (p = 0.05). Staining intensity correlated inversely with tumor size (p = 0.016) and pathologic stage (p = 0.008); as did parafibromin intensity-percentage score with pathologic stage (p = 0.03), lymphovascular invasion (p = 0.03) and cerbB2 intensity-percentage score (p = 0.04).

Conclusion: Parafibromin in breast cancer, as in parathyroid tumors, appears to have tumor suppressor functions, with loss of protein expression being associated with adverse pathologic parameters. These findings may indicate a potential role of parafibromin as a prognostic marker in breast cancer.

Key Words: immunohistochemistry, infiltrative breast carcinoma, parafibromin, tumor suppressor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.